Prospective study on the relationship between clinical efficacy of secondary hormone therapy with flutamide and neuroendocrine differentiation in patients with relapsed prostate cancer after first line hormone therapy

Scandinavian Journal of Urology

Volumn 48, Issue 5, 2014, Pages 436-444

  Hirano, Daisaku ^a   Hasegawa, Ryo ^a   Satoh, Katsuhiko ^b   Mochida, Junichi ^b   Yamanaka, Yataroh ^b   Hirakata, Hitoshi ^b   Yamaguchi, Kenya ^b   Sugimoto, Shuji ^a,c   Kawata, Nozomu ^b   Takahashi, Satoru ^b  

^a Higashi matsuyama City Municipal Hospital   (Japan)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Mitsui Hospital   (Japan)

Author keywords

Castration resistant prostate cancer; Chromogranin A; Flutamide; Neuroendocrine differentiation; Second line hormone therapy

Indexed keywords

AMINOTRANSFERASE; BICALUTAMIDE; CHROMOGRANIN A; FLUTAMIDE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANTIANDROGEN THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HORMONE RESISTANCE; HUMAN; IMMUNORADIOMETRIC ASSAY; MALE; MIDDLE AGED; NEUROENDOCRINE DIFFERENTIATION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SIDE EFFECT; TISSUE DIFFERENTIATION; TREATMENT RESPONSE; VERY ELDERLY; BLOOD; EVALUATION STUDY; NEOPLASM RECURRENCE, LOCAL; NEUROSECRETORY CELL; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CHROMOGRANIN A; FLUTAMIDE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUROENDOCRINE CELLS; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84907102620     PISSN: 21681805     EISSN: 21681813     Source Type: Journal    
DOI: 10.3109/21681805.2014.905633     Document Type: Article

References (33)

1. Crawford ED. Epidemiology of prostate cancer. Urology 2003;62:3-12.
2. Brooke GN, Parker MG, Bevan CL. Mechanisms of andro-gen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression. Oncogene 2008;27:2941-50.
3. Kojima S, Suzuki S, Akakura K, Shimbo M, Ichikawa T, Ito H. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 2004;171: 679-83.
4. Buchana G, Greenberg NM, Scher HI, Harris JM, Marshall VR, Tilley WD. Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 2001;7: 1273-81.
5. Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, Visakorpi T. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 2000;164:1992-5.
6. Hirano D, Jike T, Okada Y, Minei S, Sugimoto S, Yamaguchi K, et al. Immunohistochemical and ultrastruc-tural features of neuroendocrine differentiated carcinomas of the prostate: an immunoelectron microscopic study. Ultrastruct Pathol 2005;29:367-75.
7. Bonkhoff H, Wernert N, Dhom G, Remberger K. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate 1991;19:91-8.
8. Abrahamsson PA, Wadstrom LB, Alumets J, Falkmer S, Grimelius L. Peptide-hormone-and serotonin-immunoreactive tumour cells in carcinoma of the prostate. Pathol Res Pract 1987;182:298-307.
9. di Sant'Agnese PA, de Mesy Jensen KL. Somatostatin and/or somatostatin-like immunoreactive endocrine-paracrine cells in the human prostate gland. Arch Pathol Lab Med 1984; 108:693-6.
10. Iwamura M, Wu G, Abrahamsson PA, di Sant'Agnese P, Cockett ATK, Deftos LJ. Parathyroid hormone-related protein is expressed by prostatic neuroendocrine cells. Urology 1994;43:667-74.
11. Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004;45:587-92.
12. Hirano D, Minei S, Sugimoto S, Yamaguchi K, Yoshikawa T, Hachiya T, et al. Implications of circulating chromogranin A in prostate cancer. Scand J Urol Nephrol 2007;41:297-301.
13. Noordzij MA, van der Kwast TH, van Steenbrugge GJ, Hop WJ, Schroder FH. The prognostic influence of neuro-endocrine cells in prostate cancer: results of a long-term follow-up study with patients treated by radical prostatectomy. Int J Cancer 1995;62:252-8.
14. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-7.
15. Appetecchia M, Mecule A, Pasimeni G, Vlannucci C, De Carli P, Baldelli R, et al. Incidence of high chromogranin A serum levels in patients with non-metastatic prostate adenocarcinoma. J Exp Clin Cancer Res 2010;29:166-71.
16. DiLorenzo G, Buonerba C, Autorino R, DePlacido S, Sternberg CN. Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs 2010;70:983-1000.
17. Fowler JE Jr, Pandey P, Seaver LE, Feliz TP. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J Urol 1995;154:448-53.
18. Miyake H, Hara I, Eto H. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. BJU Int 2005;96:791-5.
19. Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, et al. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 2008;180:921-7.
20. Okihara K, Ukimura O, Kanemitsu N, Mizutani Y, Kawauchi A, Miki T. Clinical efficacy of alternative anti-androgen therapy in Japanese men with relapsed prostate cancer after first-line hormonal therapy. Int J Urol 2007;14: 128-32.
21. di Sant's Agnese PA. Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. Ann Oncol 2001;12:S135-40.
22. Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 2005;47:147-55.
23. Cussenot O, Villette JM, Valeri A, Cariou G, Desgrandchamps F, Cortesse A, et al. Plasma neuroendo-crine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol 1996;155:1340-3.
24. Berruti A, Dogliotti L, Mosca A, Bellina M, Mari M, Torta M, et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 2000;88:2590-7.
25. Ishiki S, Akakura K, Komiya A, Suzuki H, Kamiya N, Ito H. Chromogranin A concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 2002;167:512-15.
26. Angelsen A, Syversen U, Stridsberg M, Haugen OA, Mjolnerod OK, Waldum HL. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate. Prostate 1997;31:110-17.
27. Berruti A, Mosca A, Tucci M, Terrone C, Torta M, Tarabuzzi R, et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer 2005;12:109-17.
28. Culine S, El Demery M, Lamy PJ, Iborra F, Avances C, Pinguet F. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol 2007;178:844-8.
29. Sciarra A, Monti S, Gentile V, Mariotti G, Cardi A, Voria G, et al. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate 2003;55:168-79.
30. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
31. Culig Z. Androgen receptor cross-talk with cell signaling pathway. Growth Factors 2004;22:179-84.
32. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276-308.
33. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946-51.